Showing 51–75 of 107 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Terry E. Robinson, Jane Scullion
Abstract This chapter covers the key facts about tuberculosis (TB), then goes on to describe the epidemiology and pathophysiology of the disease. Risk factors, and signs and symptoms, and investigations are all covered. The treatment phase and standard drug therapies are shown, a…
Rajesh P. Pimpaldara, Keshvi Vithlani, Manisha Vasava, Rakesh Pimpaldara
Background: This study was conducted to analyse the socioeconomic and clinical profile of MDR TB patients in Rajkot to deal with this growing threat. Methodology: Total of 50 cases 0f MDR TB were analysed retrospectively in a period of 2 years during August 2013 to august 2015 to…
Vasavi Gedela, Banerji Neerugatti, Chiranjeevi Uday Kumar, Hari Jagannadha Rao
Background: MDR-TB is defined as a TB patient whose biological specimen is resistant to isoniazid and rifampicin with or without resistant to other first line drugs, based on results from quality assured laboratory. The main aim of this study was to study the treatment outcomes o…
Yin Mon Thant
Tuberculosis (TB) is well known as a major infectious disease and one of the top 10 causes of death worldwide. TB can affect anyone, everywhere but it has a predilection for those with diabetes, human immunodeficiency virus (HIV), smoking and undernutrition. Myanmar, with 54 mill…
S. N. Alyushin, Alena Skrahina, Maryna Dziusmikeyeva, Varvara Solodovnikova, Aliaksandr Skrahin
The mortality rate among tuberculosis patients requiring intensive care is high. The development of severe conditions in patients with tuberculosis may be associated with the course of the underlying disease and with concomitant pathology. The aim of this work was to study the ri…
Olivera Bojovic, D. Gudelj, S. Lucic, Božidarka Rakočević
Background: In the conditions of declining rate of drug-resistant tuberculosis and high success rate of treatment of these cases, occurrence of MDR/XDR-TB due to complexity of its treatment remains the main problem in controlling this disease in Montenegro. Methods and materials:…
Gina Oda, Cynthia Lucero‐Obusan, Patricia Schirmer, Mark Holodniy
Background: In 2018, the CDC reported that isoniazid (INH)-resistant and multidrug-resistant Mycobacterium tuberculosis (MDR-TB, ie, resistant to at least INH and rifampin) represented 9.3% and 1.5% of TB cases, respectively, in the United States. Objective: We analyzed the preva…
Pratibha Singhal, Prajay Lunia, Kapil Salgia, Iram Syed
<b>Introduction:</b> Cycloserine is a 2nd line ATT group B drug (WHO) used in doses of 10-15 mg/kg. While cycloserine induced psychiatric effects are well known but neurotoxicity is not commonly diagnosed with few reported cases. <b>Aim & Objectives:</b> To study incidence of…
Atit Puspitasari Dewi
<b>Background:</b> Drug-resistant tuberculosis (DR-TB) remains a high burden disease in Indonesia with approximately 9038 (1.6%) laboratory-confirmed DR-TB cases found in 2018. Decentralization strategy for DR-TB treatment in primary care apllied in rural area. <b>Objectives:</b>…
Olena Oliveira, Rita Gaio, Teresa Rito, Margarida Correia‐Neves, Raquel Duarte
Treatment of drug-resistant tuberculosis (TB) has become a major challenge for TB control worldwide and treatment outcomes are often suboptimal. Overall, the death rate reported by WHO was 15% among patients with multidrug-resistant tuberculosis (MDR-TB) and 26% among patients wi…
Dona Arlinda, Retna Mustika Indah, Aris Yulianto, Agus Dwi Harso, Armaji Kamaludi Syarief, et al.
Abstract Indonesia is a high burden country for tuberculosis (TB), multidrug-resistant (MDR) TB, and TB-HIV. We aimed to determine factors associated with poor TB treatment outcomes. A hospital-based TB Registry at seven referral hospitals in Java and Bali included data from pati…
Mauricio Mamani, Mario Chauca, Edward Huamani, Richard Gonzales
Objective: To determine the risk factors associated with extensively multidrug-resistant tuberculosis in multidrug-resistant patients in the DIRIS Lima Sur, 2017. Type and design: The type of research was observational and analytical, retrospective case and control. The populatio…
Vibha Mehta, Puneet Kumar Gupta, Mukesh Bairwa, Jakkula Sam Rahul
Dear Editor, In a shrinking world where diseases know no boundaries, severe global epidemics of drug resistant tuberculosis (DR-TB) pose a great health crises. Globally, World Health Organization (WHO) estimates that there are 484,000 new cases with resistance to first line drug …
Anita Kumari, Parveen Sharma, Rekha Bansal
Background: MDR-TB treatment defaulter are potentially harmful to community as these can relapse and spread infection, developed resistance to second line anti tubercular drugs and may result in to extensive drug resistant tuberculosis (XDR-TB) and major challenges for successful…
Rajendra Prasad, Harsh Saxena, Nikhil Gupta, Mohammad Tanzeem, Ronal Naorem1
Drug-resistant tuberculosis (DR-TB) has been an area of growing concern and posing threat to human health worldwide. The treatment has been defined for all types of DR-TB with or without newer anti-TB drugs. multi-DR-TB (MDR-TB) patients have now choice of two types of regimen, s…
Koku Sisay Tamirat, Gashaw Andargie, Yaregal Animut Babel
Abstract Background: Tuberculosis (TB) generally considered as an ambulatory disease. However, hospitalization remains an important component for isolation and medical stabilization of patients. Hence, this study aimed to identify factors influencing the length of hospital stay d…
Shang W, Cao G, Jing W, Liu J, Liang W, et al.
Objective Tuberculosis (TB) is a major health threat in adolescents and young adults. However, its burden in this population remains unclear. This study aimed to assess TB burden and changing trends in individuals aged 10 to 24 years from 1990 to 2019. Methods All data were obtai…
О. М. Raznatovska, А. В. Федорец, O. O. Furyk, H. I. Makurina, T. O. Hrekova, et al.
Purpose. To update the literature data with the clinical features of extensively drug-resistant tuberculosis (XDR-TB), HIV and tertiary syphilis co-infection course based on an example from own clinical experience.Materials and methods. A case report of XDR-TB with HIV and tertia…
Om Prakash Giri, Vishal Prakash Giri, Nikhil Nishant
BACKGROUND: As per WHO Global TB report (2018), 10.0 million people developed TB in 2017. India accounted for 20 % of world cases. Globally, 3.5 % of new cases and 18% of previously treated cases had MDR-TB. Corresponding figures for India are 2.8 % and 12 %. Among cases of MDR-T…
Е. Н. Филатова, Vadim Testov, Konstantin Glebov, Igor Medvinsky, Anna Panova, et al.
<b>Introduction:</b> Study of Regional mycobacterium tuberculosis (MBT) Drug Resistance (DR) allows to adopt treatment strategy in regions with high burden of XDR-TB. <b>Aims and Objectives:</b> To assess the frequency and spectrum of DR to first and second line drugs in the Ural…
Sharenja Ratnakumar, Xin Yi Choon, Moerida Belton, Paramita Palchaudhuri, Louise Cotton
<b>Introduction:</b> Although Europe represents only 3% of the global burden of tuberculosis (TB), globally it has one of the highest proportions of multidrug-resistant TB (MDRTB). TB infection in Eastern Europe remains one of the key drivers of this epidemic. We investigated the…
О.С. Шевченко, Svitlana Matveyeva, Anna Stepanenko, Olexandra Choporova, Olha Pohorielova
PECULIARITIES OF DRUG-RESISTANT TUBERCULOSIS IN UKRAINE AND KHARKIV REGION 
 Shevchenko O., Matveyeva S., Stepanenko A., Choporova O., Pohorielova O.
 Background. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis remain severe epidemic problem…
Thinley Dorji
Introduction: Multidrug resistant tuberculosis (MDR-TB) is defined as a case of tuberculosis resistant to rifampicin and isoniazid which are the first line anti tuberculosis drugs. Globally emergences of MDR-TB possess a challenge to TB control. In Bhutan, the proportion of MDR-T…
Tariq Mahmood, Pundarik Dwivedi, A.D. Shukla, Anuj Jain, Arun Kumar Verma
Introduction: Drug-resistant TB is a persistent threat, with 490 000 million cases of multidrug-resistant TB emerging in 2016.The countries with the largest numbers of MDR/RR-TB cases were China, India and the Russian Federation. Given the prolonged nature of MDR-TB, one might ex…
Mursheda Akter, Samrein B. M. Ahmed
Background: Bangladesh is ranked 6th among the Tuberculosis high burden countries. Sometimes, pulmonary tuberculosis (PTB) mimics the early symptoms of lung cancer. Developing countries like Bangladesh, with limited diagnostic facilities, often misdiagnose early lung cancer as sm…